Bhaskar Roy
Neuromuscular Medicine · New Haven, CTNPI 1629325394
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,899 of the $16,996 with a category attached, or 70.0%. 6 manufacturers reported payments, led by Sanofi at 38.8% of the total.
Across 21 payments — averaging $809.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$7K
- Argenx US, Inc.$4K
- AstraZeneca$4K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- CSL Behring$95
- Grifols USA, LLC$15
Across 146 payments — averaging $3548.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Argenx US, Inc.$185K
- Takeda Pharmaceuticals U.S.A., Inc.$157K
- Sanofi US Services Inc.$133K
- AstraZeneca$30K
- Janssen Research & Development, LLC$13K
What the payments were for
- Consulting fees$11,89970%
- Speaking & faculty fees$2,97017%
- Travel & lodging$1,65810%
- Food & beverage$4683%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 1 | $6,590 |
| Argenx US, Inc. | 6 | $4,414 |
| AstraZeneca | 10 | $4,072 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $1,809 |
| CSL Behring | 1 | $95 |
| Grifols USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neuromuscular medicine providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 49 | $700,340 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 74 | $634,954 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 37 | $576,049 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 18 | $79,014 |
| NeurontinGabapentin | 11 | $20,527 |
| Gabapentin | 120 | $2,984 |
| Pregabalin | 47 | $1,574 |
| Baclofen | 23 | $690 |
| Mycophenolate Mofetil | 12 | $361 |
| Duloxetine Hcl | 11 | $341 |
| Ropinirole Hcl | 11 | $242 |
| Prednisone | 18 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen, Hizentra | $95 | $713,96892 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $1,809 | $700,34049 claims |
| Grifols USA, LLCGamunex-C | $15 | $576,04937 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Connecticuton file to place this against a meaningful peer group, so we don't.
Other neuromuscular medicine in New Haven
- Ylec Cardenas CastilloNew Haven$1K
- Uzma UsmanNew Haven$425
- Kunal DesaiNew Haven$259
- Bertrand TsengNew Haven$125
- John TauroNorwich$54K
- Sasa ZivkovicGuilford$37K
- Barry GordonMeriden$3K
- Kevin FeliceNew Britain$2K
- David TinklepaughMystic$2K
- Arpad FejosMiddletown$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.